Skip to main content
. 2010 Dec 1;13(1):51–60. doi: 10.1093/neuonc/noq150

Fig. 4.

Fig. 4.

Effect of vascular targeting agents on brain tumor volume. Rats with intracerebral LX-1 SCLC xenografts received intetumumab (30 mg/kg i.v.; circles) or bevacizumab (45 mg/kg i.v.; triangles), in comparison with untreated controls (squares). Normalized tumor volume changes over time were assessed on anatomical MRI scans obtained using T1-weighted with GBCA (A) or T2-weighted (B) sequences. The mean and the standard deviation are indicated for n = 4–6 rats per time point, showing decreased growth rate in bevacizumab-treated tumors. In comparison with baseline, *P < .05 and **P < .001; in comparison with control at each time point, •P < .05 and ••P < .001. C shows final tumor volumes (individual animals and means) assessed on T1-weighted + GBCA MRI, T2-weighted MRI, and histological sections.